KR100690037B1 - 콜렌산 아미드 및 이를 함유하는 약학적 조성물 - Google Patents

콜렌산 아미드 및 이를 함유하는 약학적 조성물 Download PDF

Info

Publication number
KR100690037B1
KR100690037B1 KR1020007009596A KR20007009596A KR100690037B1 KR 100690037 B1 KR100690037 B1 KR 100690037B1 KR 1020007009596 A KR1020007009596 A KR 1020007009596A KR 20007009596 A KR20007009596 A KR 20007009596A KR 100690037 B1 KR100690037 B1 KR 100690037B1
Authority
KR
South Korea
Prior art keywords
group
enoic acid
formula
amide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007009596A
Other languages
English (en)
Korean (ko)
Other versions
KR20010041446A (ko
Inventor
헤세로버트헨리
세티선다라카투갬스리니바사세티
람고팔말라티
Original Assignee
리서치 인스티튜트 포 메디신 앤드 케미스트리 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리서치 인스티튜트 포 메디신 앤드 케미스트리 인코포레이티드 filed Critical 리서치 인스티튜트 포 메디신 앤드 케미스트리 인코포레이티드
Publication of KR20010041446A publication Critical patent/KR20010041446A/ko
Application granted granted Critical
Publication of KR100690037B1 publication Critical patent/KR100690037B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020007009596A 1998-03-06 1999-03-08 콜렌산 아미드 및 이를 함유하는 약학적 조성물 Expired - Fee Related KR100690037B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9804861.4 1998-03-06
GBGB9804861.4A GB9804861D0 (en) 1998-03-06 1998-03-06 Chemical compounds

Publications (2)

Publication Number Publication Date
KR20010041446A KR20010041446A (ko) 2001-05-25
KR100690037B1 true KR100690037B1 (ko) 2007-03-08

Family

ID=10828156

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007009596A Expired - Fee Related KR100690037B1 (ko) 1998-03-06 1999-03-08 콜렌산 아미드 및 이를 함유하는 약학적 조성물

Country Status (15)

Country Link
US (1) US7235552B1 (enExample)
EP (1) EP1060188A1 (enExample)
JP (1) JP2002505336A (enExample)
KR (1) KR100690037B1 (enExample)
CN (1) CN1177860C (enExample)
AU (1) AU752992B2 (enExample)
CA (1) CA2319763C (enExample)
CZ (1) CZ298478B6 (enExample)
GB (1) GB9804861D0 (enExample)
HU (1) HUP0100854A3 (enExample)
IL (1) IL138137A (enExample)
NO (1) NO317378B1 (enExample)
NZ (1) NZ506139A (enExample)
WO (1) WO1999045024A1 (enExample)
ZA (1) ZA991841B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ523042A (en) * 2000-05-11 2004-05-28 Res Inst Medicine Chem 2-substituted pregna-1, 3, 5 (10) -triene and chola-1, 3, 5 (10)-triene derivatives and their biological activity
EP1514874A1 (en) * 2003-07-28 2005-03-16 Schering Aktiengesellschaft Thiomorpholino steroid compounds, the use thereof for the preparation of meiosis regulating medicaments and method for the preparation thereof
WO2009059239A2 (en) * 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
WO2010065936A1 (en) 2008-12-04 2010-06-10 Chongxi Yu High penetration compositions and their applications
US8987235B2 (en) 2011-05-17 2015-03-24 Wisconsin Alumni Research Foundation N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-vitamin D analogs and their uses
CA2842462C (en) 2011-07-20 2020-01-28 Brigham Young University Hydrogel materials incorporating eluting ceragenin compound
RU2669800C2 (ru) 2013-03-15 2018-10-16 Брихэм Янг Юниверсити Способы лечения воспаления, аутоиммунных расстройств и боли
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
US9434759B1 (en) * 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
EP3275888B1 (en) * 2016-07-28 2019-09-25 Council of Scientific & Industrial Research Progesterone-cationic lipid hybrid as anticancer agent and the process of synthesis thereof
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth
WO2023205801A2 (en) 2022-04-22 2023-10-26 Asteroid Therapeutics Steroidal compositions and methods of treating lipogenic cancers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1512326A (fr) * 1964-03-27 1968-02-09 Roussel Uclaf Nouveaux stéroïdes azotés et procédé de préparation
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
US4172076A (en) * 1977-04-04 1979-10-23 Diamond Shamrock Corporation Process for preparing steroidal acids and their intermediate derivatives
DE2920092A1 (de) * 1978-05-19 1979-11-29 Wisconsin Alumni Res Found Antivitamin d-verbindungen und diese enthaltende pharmazeutische zusammensetzungen
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
US5494905A (en) * 1991-11-07 1996-02-27 Research Institute For Medicine And Chemistry Vitamin D amide derivatives
JP3493037B2 (ja) * 1991-12-18 2004-02-03 中外製薬株式会社 ２２−オキサコレカルシフェロール誘導体とその製造方法
IL105050A0 (en) * 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
WO1997042215A1 (en) * 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Process for preparing 27-hydroxy cholesterol and related derivatives
PL334840A1 (en) * 1997-01-24 2000-03-27 Univ California Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation

Also Published As

Publication number Publication date
GB9804861D0 (en) 1998-04-29
ZA991841B (en) 1999-09-08
AU3267599A (en) 1999-09-20
CZ20003253A3 (cs) 2001-03-14
CA2319763A1 (en) 1999-09-10
US7235552B1 (en) 2007-06-26
IL138137A (en) 2005-11-20
CA2319763C (en) 2008-01-15
KR20010041446A (ko) 2001-05-25
JP2002505336A (ja) 2002-02-19
IL138137A0 (en) 2001-10-31
EP1060188A1 (en) 2000-12-20
AU752992B2 (en) 2002-10-03
CZ298478B6 (cs) 2007-10-17
NO20004399D0 (no) 2000-09-04
NO20004399L (no) 2000-11-03
CN1292797A (zh) 2001-04-25
CN1177860C (zh) 2004-12-01
HUP0100854A3 (en) 2002-09-30
NO317378B1 (no) 2004-10-18
WO1999045024A1 (en) 1999-09-10
NZ506139A (en) 2003-06-30
HUP0100854A2 (hu) 2001-09-28

Similar Documents

Publication Publication Date Title
KR100690040B1 (ko) 치료용 ｃ17-알킬 측쇄 및 방향족 ａ-고리를 갖는스테로이드 화합물
KR100690037B1 (ko) 콜렌산 아미드 및 이를 함유하는 약학적 조성물
AU682195B2 (en) New 11-benzaldoxime-estradiene-derivatives, methods for their production and pharmaceuticals containing these substances
JP3282811B2 (ja) 化学的化合物
JP2002517405A (ja) アゴニストまたはアンタゴニストホルモン特性を有する１７β−ニトロ−１１β−アリルステロイドとその誘導体
EP0468042B1 (en) HOMOLOGATED VITAMIN D2 COMPOUNDS AND THE CORRESPONDING 1alpha-HYDROXYLATED DERIVATIVES
KR100361556B1 (ko) 비타민-d아미드유도체
US6372926B2 (en) 17-side chain alkynyl-and 20-oxopregna-derivatives of vitamin D, methods for their production and pharmaceutical compositions thereof
US6218425B1 (en) 8-substituted B-nor-6-Thiaequilenin compounds having activity as selective estrogen receptor modulators
RU2137777C1 (ru) ПРОИЗВОДНЫЕ 11β-БЕНЗАЛЬДОКСИМ-ЭСТРА-4,9-ДИЕНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100227

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100227